Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06622798
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-29
Brief Title:
Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Retrospective Study Exploring the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study plans to retrospectively include 470 initial surgical specimens from 470 patients with epithelial ovarian fallopian tube or primary peritoneal cancers who were treated with PARPi maintenance therapy in the hospital from 201801 to 202401 All patients included would be scored by the proprietary HRD ADx-GSS algorithm with the detecting results of the three genomic statuses including heterozygous omission LOH telomere allelic imbalance TAI and large-segment translocation LST Finally the correlation between the HRD scores and the prognosis of Chinese ovarian cancer patients and the efficacy of using PARPi as maintenance treatment would be explored
Detailed Description:
Although most advanced ovarian cancers achieve clinical remission after conventional initial treatment the recurrence rate is still high in clinics Poly ADP-ribose polymerase inhibitor PARPi is widely used in the maintenance treatment of ovarian cancer after chemotherapy to prolong the time to recurrence and its main mechanism is to inhibit the repair of single-stranded DNA damage in tumour cells which is synthetically lethal in the tumour cells with mutations in the BRCA12 gene Numerous studies have shown that homologous recombination deficiency HRD exists in about 50 of epithelial ovarian cancer patients and has been confirmed to be a predictor of ovarian cancer patients response to PARPi therapy However up to now there is still no uniform scoring and threshold standard for HRD detection in China With the increasing attention of HRD detection in clinical diagnosis and treatment acknowledged standards of HRD scoring algorithms and thresholds are essential Using a retrospective Thus this observational and retrospective study intends to enroll 470 patients with epithelial ovarian fallopian tube or primary peritoneal cancers who were treated with PARPi maintenance therapy in the hospital from 201801 to 202401 All patients included would be scored by the proprietary HRD ADx-GSS algorithm with the detecting results of the three genomic statuses including heterozygous omission LOH telomere allelic imbalance TAI and large-segment translocation LST Finally the correlation between the HRD scores and the prognosis of Chinese ovarian cancer patients and the efficacy of using PARPi as maintenance treatment would be explored
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None